Skip to main navigation Skip to search Skip to main content

Rare deleterious germline variants and risk of lung cancer

  • Yanhong Liu
  • , Jun Xia
  • , James McKay
  • , Spiridon Tsavachidis
  • , Xiangjun Xiao
  • , Margaret R Spitz
  • , Chao Cheng
  • , Jinyoung Byun
  • , Wei Hong
  • , Yafang Li
  • , Dakai Zhu
  • , Zhuoyi Song
  • , Susan M Rosenberg
  • , Michael E Scheurer
  • , Farrah Kheradmand
  • , Claudio W Pikielny
  • , Christine M Lusk
  • , Ann G Schwartz
  • , Ignacio I Wistuba
  • , Michael H Cho
  • Edwin K Silverman, Joan Bailey-Wilson, Susan M Pinney, Marshall Anderson, Elena Kupert, Colette Gaba, Diptasri Mandal, Ming You, Mariza de Andrade, Ping Yang, Triantafillos Liloglou, Michael P A Davies, Jolanta Lissowska, Beata Swiatkowska, David Zaridze, Anush Mukeria, Vladimir Janout, Ivana Holcatova, Dana Mates, Jelena Stojsic, Ghislaine Scelo, Paul Brennan, Geoffrey Liu, John K Field, Rayjean J Hung, David C Christiani, Christopher I Amos
  • Baylor College of Medicine
  • International Agency for Research on Cancer
  • Dartmouth College
  • Wayne State University
  • The University of Texas MD Anderson Cancer Center
  • Brigham and Women's Hospital
  • National Human Genome Research Institute
  • University of Cincinnati
  • University of Toledo
  • Louisiana State University Health Sciences Center
  • Nutrition Medical College of Wisconsin
  • Mayo Clinic College of Medicine and Science
  • Liverpool John Moores University
  • M. Sklodowska-Curie National Research Institute of Oncology
  • Nofer Institute of Occupational Medicine
  • Russian N.N. Blokhin Cancer Research Centre
  • Palacký University Olomouc
  • Charles Darwin University
  • NIHR
  • Clinical Center of Serbia
  • Princess Margaret Cancer Centre
  • Lunenfeld-Tanenbaum Research Institute
  • Harvard T.H. Chan School of Public Health
  • University of Liverpool

Research output: Contribution to journalArticle (journal)peer-review

Abstract

Recent studies suggest that rare variants exhibit stronger effect sizes and might play a crucial role in the etiology of lung cancers (LC). Whole exome plus targeted sequencing of germline DNA was performed on 1045 LC cases and 885 controls in the discovery set. To unveil the inherited causal variants, we focused on rare and predicted deleterious variants and small indels enriched in cases or controls. Promising candidates were further validated in a series of 26,803 LCs and 555,107 controls. During discovery, we identified 25 rare deleterious variants associated with LC susceptibility, including 13 reported in ClinVar. Of the five validated candidates, we discovered two pathogenic variants in known LC susceptibility loci, ATM p.V2716A (Odds Ratio [OR] 19.55, 95%CI 5.04-75.6) and MPZL2 p.I24M frameshift deletion (OR 3.88, 95%CI 1.71-8.8); and three in novel LC susceptibility genes, POMC c.*28delT at 3' UTR (OR 4.33, 95%CI 2.03-9.24), STAU2 p.N364M frameshift deletion (OR 4.48, 95%CI 1.73-11.55), and MLNR p.Q334V frameshift deletion (OR 2.69, 95%CI 1.33-5.43). The potential cancer-promoting role of selected candidate genes and variants was further supported by endogenous DNA damage assays. Our analyses led to the identification of new rare deleterious variants with LC susceptibility. However, in-depth mechanistic studies are still needed to evaluate the pathogenic effects of these specific alleles.

Original languageEnglish
Article number12
Pages (from-to)12
Journalnpj Precision Oncology
Volume5
Issue number1
DOIs
Publication statusPublished - 16 Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Rare deleterious germline variants and risk of lung cancer'. Together they form a unique fingerprint.

Cite this